|
Author:
|
Montaner Tarbes, Sergio Roberto; Novell, Elena; Tarancón, Vicens; Borrás, Francesc E.; Montoya, Maria; Fraile Sauce, Lorenzo José; del Portillo, Hernando A.
|
|
Notes:
|
The Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is the etiological agent of one of the
most important swine diseases with a significant economic burden worldwide. Unfortunately, available
vaccines are partially effective highlighting the need of novel approaches. Previously, antigenic viral
proteins were described in serum-derived extracellular vesicles (EVs) from pigs previously infected with
PRRSV. Here, a targeted-pig trial was designed to determine the safety and immunogenicity of such
extracellular vesicles enriched fractions. Our results showed that immunizations with EV-enriched
fractions from convalescence animals in combination with montanide is safe and free of virus as
immunizations with up-to two milligrams of EV-enriched fractions did not induce clinical symptoms,
adverse effects and detectable viral replication. In addition, this vaccine formulation was able to elicit
specific humoral IgG immune response in vaccinated animals, albeit variably. Noticeably, sera from
vaccinated animals was diagnosed negative when tested for PRRSV using a commercial ELISA test;
thus, indicating that this new approach differentiates vaccinated from infected animals. Lastly, after
priming animals with EV-enriched fractions from sera of convalescence animals and boosting them with
synthetic viral peptides identified by mass spectrometry, a distinctive high and specific IFN-γ response
was elicited. Altogether, our data strongly suggest the use of serum EV-enriched fractions as a novel
vaccine strategy against PRRSV.
Anti-CD9, Anti-CD63 and anti-CD81 antibodies were kindly donated by Francisco Sánchez-Madrid and Maria Yañez-Mo, Hospital de la Princesa, Madrid, Spain. The authors wish to particularly thank Glòria Abella for her collaboration in conducting the field study and to Marta Alcobé, Miriam Moron Font and Paula Crego Mendez for technical assistance. This study received support from Innovex Therapeutics S.L., Pinsos del Segre SA, Granja Casanyé, Grup de Sanejament Porci (GSP, Lleida, Spain) and the FEDER project (COMRDI16-1-0035-03). Sergio Montanter-Tarbes is an industrial doctorate awarded by the Government of Catalonia, Spain (No. 2014 DI 044). ISGlobal and IGTP are members of the CERCA Programme, Generalitat de Catalunya. |
